Researches above indicate that the dual-targeted therapy regimen of dabrafenib combined with trametinib exhibits good anti-tumor effects in patients with BRAF-V600-mutant NSCLC, whether as a first line or subsequent line of treatment. This evidence concerns the gene BRAF and neoplasm.